Life sciences firm Promentis Pharmaceuticals raises $2.9m to develop drugs targeting schizophrenia and other central nervous system disorders.

Promentis Pharmaceuticals, a spin-out from the universities of Marquette and Wisconsin-Milwaukee, has secured $2.9m in funding.

Germany-based investment firm Black Horse Investments led the round, which was joined by angel network Golden Angels Investors and private investors. The Milwaukee-based firm previously held a series A round, led by Golden Angels, which was worth $1.94m. It has also attracted $1.8m from the National Instititues of Health, and a further $299,000 from the research foundation of actor Michael J. Fox, who suffers…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?